Loading...
Loading...
Genetic Technologies Limited
is pleased to
announce a partnership with international race car driver Ms. Pippa Mann to promote BREVAGenplus®,
the Company's first-in-class, clinically validated risk assessment test for sporadic breast cancer. This
agreement marks the Company's first marketing program, with a national reach, promoting
BREVAGenplus in the U.S. and is reflective of Ms. Mann's commitment to working with research
organisations and corporations who share her passion for reducing the impact that breast cancer has on
women. In addition to Genetic Technologies, Ms. Mann has an established partnership with Susan G.
Komen®, the world's largest breast cancer organisation, which funds more breast cancer research than
any other non-profit while providing screening, education, treatment and psychosocial support programs.
"This is an exciting time for the Company as we commence this robust partnership with Pippa. She
represents everything we stand for as a company and shares our passion for the integral role
BREVAGenplus can play in women's health. She is truly a next generation athlete who is steadfast in
leveraging her brand power to promote breast cancer awareness and raise money to help fund cures.
Prevention and early detection of breast cancer are central to this mission and the genesis behind her
desire to raise the profile of BREVAGenplus as an important breast cancer risk assessment and
preventative treatment management tool," commented Eutillio Buccilli, Executive Director and Chief
Executive Officer of Genetic Technologies.
The partnership agreement is inclusive of the BREVAGenplus logo represented on Pippa's racing car
along with racing and promotional apparel. Ms. Mann will also participate at select BREVAGenplus
oriented events and other promotional activities over the course of 2016 (e.g. speaking engagements,
social media, print and video campaigns), and related sales support activities. The 100th running of the
Indianapolis 500 on May 29, 2016 will serve as the official launch of the partnership program. The "Indy
500" is the largest single day sporting event in the world and offers important promotional opportunities
during the month long lead-up to the race, which includes 12 days of on-track activities and hospitality
event participation. Ms. Mann is one of only 9 female athletes to ever compete in the "Indy 500" and the
only female driver to start in the race over the past 3 consecutive years.
"From my perspective, the partnership is comprehensive in tone, scope and intent. I am honoured to be
working with such a progressive company and, most important, to represent a game-changing product
that deserves broader exposure. The racing community and its fans are diverse in every statistical
category and I look forward to working with the Genetic Technologies team to raise the profile of
BREVAGenplus among this important audience and beyond," commented Pippa Mann.
For personal use only
Genetic Technologies Limited • Website: www.gtglabs.com • Email: info@gtglabs.com ABN 17 009 212 328
Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 • Fax +61 3 8412 7040
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in